Real-World Data on the Effectiveness of Ustekinumab and Risankizumab for Crohn’s Disease
RZB may offer greater short-term efficacy than UST, with an acceptable safety profile in real-world settings.
Authors
- K Takenaka (ORCID: https://orcid.org/0000-0002-7861-8383)
- Shuji Hibiya (ORCID: https://orcid.org/0000-0001-8823-7755)
- Ami Kawamoto (ORCID: https://orcid.org/0000-0002-8549-4999)
- Toshimitsu Fujii (ORCID: https://orcid.org/0000-0003-3048-7270)
- Ryo Morikawa
- Hiromichi Shimizu (ORCID: https://orcid.org/0000-0003-3268-0613)
- Kazuo Ohtsuka (ORCID: https://orcid.org/0000-0002-2409-9709)
- Ryuichi Okamoto (ORCID: https://orcid.org/0000-0002-7047-571X)
- Akiko Tamura
Publication Details
- Journal
- Inflammatory Intestinal Diseases
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1159/000547048
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science